IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Glenmark Life Sciences IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 1513.60 Cr. The company is based in Solapur and caters to Pharmaceutical sector. Bob Capital Markets , Bofa Securities India , Dam Capital Advisors (Formerly Idfc Securities ) , Goldman Sachs (India) Securities are the merchant bankers of Glenmark Life Sciences IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 16th April 2021.
Glenmark Life Sciences IPO posted revenues of ₹ 1,885.17 Cr. and PAT of ₹ 351.58 Cr. in FY25 on annualised basis.
Revenue:
₹ 1,885.17 Cr.
EBITDA Margin:
31.40
% 
Net Worth: ₹ 752.75 Cr.
Market Capitalisation:
[●]
P/E:
25.09 times
P/BV: [●]
EV/EBITDA: -0.20 times
Financial results of Glenmark Life Sciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY21 | FY20 | FY19 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 1997.08 | 1725.60 | 1475.40 | ||
| Net Worth | 752.75 | 401.69 | 88.13 | ||
| Total Debt | [●] | 0.02 | 0.02 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
1885.17 | 1537.31 | 886.42 | ||
EBITDA
EBITDA on annualised basis |
591.89 | 483.95 | 248.16 | ||
PAT
PAT on annualised basis |
351.58 | 313.10 | 195.59 | ||
Glenmark Life Sciences IPO PAT Margin is 18.65 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Glenmark Life Sciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY21 | FY20 | FY19 |
|---|---|---|---|
| EBITDA Margin (%) | 31.40 | 31.48 | 28.00 |
| PAT Margin (%) | 18.65 | 20.37 | 22.07 |
| EPS (₹) | 32.61 | 29.04 | 24.64 |
| ROE (%) | 46.71 | 77.95 | 221.93 |
| ROCE (%) | [●] | [●] | [●] |
| ROA (%) | 17.60 | 18.14 | 13.26 |
| Debt to Equity | [●] | 0.00 | 0.00 |
The market Capitalisation of Glenmark Life Sciences IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Glenmark Life Sciences IPO prospectus highlights an Return on Equity (ROE) of 46.71 % , Return on Assets (ROA) of 17.60 %, and an EBITDA Margin of 31.40 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Glenmark Life Sciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Glenmark Life Sciences IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Glenmark Life Sciences IPO has a Price-to-Earnings (PE) ratio of 25.09 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Glenmark Life Sciences IPO reported revenue of ₹ 1885.98 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Glenmark Life Sciences IPO provide insights into sales growth, market demand, and business scalability.
Glenmark Life Sciences recorded an EBITDA of ₹ 591.89 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Glenmark Life Sciences Profit After Tax (PAT) is ₹ 351.58 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 1,885.17 Cr.
EBITDA Margin:
31.40
%
Net Worth: ₹ 752.75 Cr.
Market Capitalisation:
[●]
P/E:
25.09 times
P/BV: [●]
EV/EBITDA:
[●]
Glenmark Life Sciences operates in Pharmaceutical and Developer And Manufacturer. The Issue is listed on BSE,NSE in Aug, 2021. Glenmark Life Sciences IPO size was 1513.60 with Issue price of 720.00 .
Merchant Banker(s) of Glenmark Life Sciences IPO: Bob Capital Markets Limited , Bofa Securities India Limited , Dam Capital Advisors Limited (Formerly Idfc Securities Limited) , Goldman Sachs (India) Securities Private Limited
Glenmark Life Sciences IPO subscription was 44.17 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Glenmark Life Sciences IPO listed at a listing price of 748.20 against the offer price of 720.00.
The current market price of Glenmark Life Sciences is 1058.30.
Why Us?
